GlassScriptPhysician profile
Fariba Farhidvash
NPI 1831277946
$14,841.30
in general payments reported to CMS, 2019-2025
60 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,841 · 2020: $851 · 2021: $946 · 2022: $1,228 · 2023: $3,027 · 2024: $4,482 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,227 · Consulting Fee: $3,040 · Travel and Lodging: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,226.59 |
| Consulting Fee | $3,040.00 |
| Travel and Lodging | $707.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,861.48 | 2019-2025 | Briviact, Zilbrysq, Fintepla |
| Abbvie INC. | $2,798.27 | 2019-2025 | |
| Livanova USA, INC. | $937.77 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $865.80 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Sk Life Science, INC. | $611.01 | 2020-2025 | |
| Allergan, INC. | $428.83 | 2019-2020 | |
| Lilly USA, LLC | $369.59 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Novartis Pharmaceuticals Corporation | $346.23 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $337.03 | 2019-2025 | Ingrezza |
| Biogen, INC. | $324.56 | 2019-2023 | Tysabri, Vumerity |
| Lundbeck LLC | $280.88 | 2019-2025 | Vyepti |
| Eisai INC. | $267.02 | 2019-2021 | |
| Greenwich Biosciences, INC. | $262.19 | 2019-2021 | |
| Amgen INC. | $261.36 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $213.12 | 2019-2023 | Ultomiris |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fariba Farhidvash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.